Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA   US9216591084

News SummaryMost relevantAll newsSector news 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

04/16/2012 | 07:50am US/Eastern

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207;

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
React to this article
08:33a VANDA PHARMACEUTICALS : declares Tradipitant Phase II Proof of Concept study res..
03/05 VANDA PHARMACEUTICALS : VNDA) is Trading Lower on Unusual Volume for March 05
03/04 VANDA PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8-..
03/04 VANDA PHARMACEUTICALS : Announces Tradipitant Phase II Proof of Concept Study Re..
02/25 VANDA PHARMACEUTICALS : Reports Fourth Quarter 2014 and Full Year 2014 Financial..
02/19 VANDA PHARMACEUTICALS : posts 4Q profit
02/19 VANDA PHARMACEUTICALS : Results of Operations and Financial Condition, Financial..
02/19 VANDA PHARMACEUTICALS : Reports Fourth Quarter 2014 and Full Year 2014 Financial..
02/02 VANDA PHARMACEUTICALS : to Announce Fourth Quarter 2014 Financial Results on Feb..
01/29 VANDA PHARMACEUTICALS : to Participate in the Canaccord Genuity Rare Disease, Bi..
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes